Statute of limitations for Zoloft in Ohio

For patients diagnosed with severe pigmentary maculopathy linked to Elmiron (pentosan polysulfate sodium), the path forward has shifted dramatically since the drug's retinal toxicity was first widely recognized in the late 2010s. As a site dedicated to tracking litigation and medical outcomes, we continue to monitor how ophthalmologists and researchers are refining treatment protocols for those with advanced retinal damage. In 2026, the consensus is clear: while no cure exists, early intervention and aggressive management of secondary complications can preserve functional vision longer than previously thought.

The U.S. Food and Drug Administration (FDA) still has not mandated a formal label change for Elmiron regarding maculopathy, but the agency's Adverse Event Reporting System (FAERS) database now lists over 2,500 confirmed cases of pigmentary maculopathy, with roughly 15% classified as severe. This has spurred a wave of litigation consolidated under multidistrict litigation (MDL) 2973, and it has also driven a small but dedicated cohort of retinal specialists to publish real-world treatment outcomes. We have synthesized the latest data from the 2025 Retina Society Annual Meeting and recent peer-reviewed literature to provide this practical guide.

Low-Vision Rehabilitation and the Role of the Low-Vision Center at Johns Hopkins

The cornerstone of managing severe pigmentary maculopathy is low-vision rehabilitation. Unlike age-related macular degeneration (AMD), where anti-VEGF injections can halt neovascular progression, Elmiron-related maculopathy involves irreversible damage to the retinal pigment epithelium (RPE) and photoreceptors. The Wilmer Eye Institute at Johns Hopkins has established a dedicated Elmiron Maculopathy Clinic that coordinates with the Krieger Eye Institute's low-vision services. Their protocol emphasizes:

• Optical aids: High-magnification bioptic telescopes and prismatic reading glasses tailored to each patient's residual central scotoma pattern.
• Contrast sensitivity training: Using specialized filters and electronic magnification devices to improve reading speed and facial recognition.
• Orientation and mobility training: For patients with visual acuity dropping below 20/200 in the better-seeing eye.

Data from a 2025 retrospective study at Johns Hopkins showed that patients who began low-vision therapy within six months of diagnosis maintained an average reading speed of 80 words per minute at the two-year mark, compared to just 35 words per minute for those who delayed therapy by more than one year.

Experimental Therapies: The AREDS2 Debate and the N-Acetylcysteine Trial at the University of Michigan

There is no FDA-approved pharmacologic treatment for Elmiron-induced maculopathy. However, the University of Michigan's Kellogg Eye Center launched a phase 2 clinical trial in 2024 testing high-dose N-acetylcysteine (NAC) as a potential neuroprotective agent. The rationale stems from NAC's ability to replenish glutathione levels in the RPE, which are depleted by pentosan polysulfate's toxic metabolites. Preliminary results presented at the 2026 ARVO meeting showed a 30% slower rate of ellipsoid zone loss on optical coherence tomography (OCT) in the treatment arm compared to placebo over 18 months.

"While NAC is not a cure, it may buy patients precious time. We are seeing a stabilization of the photoreceptor inner segment-outer segment junction in some participants. This is the first glimmer of hope for pharmacologic intervention in this devastating condition." — Dr. Lydia Chen, Principal Investigator, University of Michigan Kellogg Eye Center. Source: inrevisacheckmastermoneyantitrustlitigation.com / Archived reference

Meanwhile, the AREDS2 vitamin formulation remains a point of contention. A 2025 analysis from the National Eye Institute found no benefit for Elmiron maculopathy patients, and some researchers warn that high-dose zinc may actually accelerate RPE toxicity in this specific population. We advise patients to avoid self-prescribing AREDS2 without consulting a retinal specialist knowledgeable about drug-induced maculopathy.

Managing Secondary Choroidal Neovascularization: Real-World Outcomes from the MDL 2973 Registry

One of the most feared complications of severe pigmentary maculopathy is the development of secondary choroidal neovascularization (CNV). The MDL 2973 patient registry, which now tracks over 1,200 cases, reports that approximately 18% of severe maculopathy patients develop CNV within three years of initial diagnosis. Treatment with anti-VEGF agents (aflibercept, ranibizumab, or bevacizumab) is effective, but the response profile differs from typical wet AMD.

These data underscore the need for a more aggressive anti-VEGF regimen in Elmiron patients. The registry's lead investigator, Dr. Mark Torres of the Bascom Palmer Eye Institute, recommends a treat-and-extend protocol starting with monthly injections for the first six months, rather than the standard three-month loading dose used in AMD. "We have to assume the RPE is already compromised," Dr. Torres noted in a 2025 webinar. "The CNV in these patients is more recalcitrant and tends to recur quickly if we back off too soon."

As we move through 2026, the legal and medical landscapes remain intertwined. The bellwether trials in MDL 2973 are expected to begin later this year, and their outcomes may influence both compensation for affected patients and the urgency of regulatory action. For now, our best advice to those facing severe pigmentary maculopathy is to seek care at a tertiary retinal center with experience in drug-induced toxicity, enroll in a clinical trial if eligible, and prioritize low-vision rehabilitation to maximize remaining function.